RxDoctor Payments DataLook up a doctor →

Clarence Runnels

Psychiatric/Mental Health · Creedmoor, NCNPI 1487129649

Payments from drug & device makers

$339,155in general payments, 2019–2025

Across 1,153 payments — averaging $294.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$194K
  • Neurocrine Biosciences, Inc.$67K
  • Axsome Therapeutics, Inc.$49K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$14K
  • Alkermes, Inc.$6K
  • Idorsia Pharmaceuticals US Inc$3K
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$48,79014%
  • Speaking & faculty fees$223,40266%
  • Travel & lodging$47,39114%
  • Food & beverage$19,3116%
  • Education$2610%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$339,155 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$20,526
Medicare patients
48
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate32$260,921
Austedo XrDeutetrabenazine11$56,365
TrintellixVortioxetine Hydrobromide28$22,658
AuvelityDextromethorphan Hbr/Bupropion15$19,810
BelsomraSuvorexant21$10,795
VyvanseLisdexamfetamine Dimesylate24$8,963
Vilazodone Hcl67$7,278
Lisdexamfetamine Dimesylate29$6,990
Ramelteon19$5,621
Lurasidone Hcl38$5,276
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine132$3,379
Desvenlafaxine Succinate ErDesvenlafaxine Succinate61$3,299
Clonazepam309$3,118
Aripiprazole65$2,941
Bupropion XlBupropion Hcl119$2,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$67,359$260,92132 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$854$56,36511 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$239$31,62252 claims
Axsome Therapeutics, Inc.Auvelity$48,659$19,81015 claims
Almatica Pharma LLCSertraline Hcl$94$45738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Creedmoor

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →